ArticlePloS one2013
MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies.PloS one · 2014Pooled it
- Retraction: MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2.PloS one · 2023Article
- Retraction: MicroRNA-219-2-3p Functions as a Tumor Suppressor in Gastric Cancer and Is Regulated by DNA Methylation.PloS one · 2023Article
- Tumor-Progressive Mechanisms Mediating miRNA-Protein Interaction.International journal of molecular sciences · 2021Review
- Expression of microRNAs targeting heat shock protein B8 during in vitro expansion of dental pulp stem cells in regulating osteogenic differentiation.Archives of oral biology · 2019Article
- microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression.Nature communications · 2019Article
- MicroRNA‑219 overexpression serves a protective role during liver fibrosis by targeting tumor growth factor β receptor 2.Molecular medicine reports · 2019Article
- Article
- DNA methylation contributes to silencing the expression of linc00086 in gastric cancer.Oncology letters · 2018Article
- Epigenetics and MicroRNAs in Cancer.International journal of molecular sciences · 2018Review
- Epigenetic silencing ofOncotarget · 2018Article
- MicroRNA-219 exerts a tumor suppressive role in glioma via targeting Sal-like protein 4.Experimental and therapeutic medicine · 2017Article
- Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.Oncotarget · 2017Article
- Animal Models to Study MicroRNA Function.Advances in cancer research · 2017Review
- Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.Oncotarget · 2016Review
- Non-coding RNA/microRNA-modulatory dietary factors and natural products for improved cancer therapy and prevention: Alkaloids, organosulfur compounds, aliphatic carboxylic acids and water-soluble vitamins.Non-coding RNA research · 2016Review
- Article
- Article
- Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis.World journal of gastroenterology · 2015Review
- Dysregulation of non-coding RNAs in gastric cancer.World journal of gastroenterology · 2015Review
Corrections and comments
- Retraction · 2023-03-29Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Image · Compromised Peer Review ·
- Retracted
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND
aimsGastric cancer is the most frequent gastrointestinal tumor in adults and is the most lethal form of human cancer. Despite of the improvements in treatments, the underlying mechanism of gastric carcinogenesis is not well known. To define novel modulators that regulate susceptibility to tumorgenesis, we focused on miR-219-2-3p.
methodsQuantitative RT-PCR was employed to investigate the level of miR-219-2-3p in gastric cancer (GC) tissues (n = 113) and their matched adjacent normal tissues (n = 113). In vitro cell proliferation, apoptosis assays, cell migration, and invasion assays were performed to elucidate biological effects of miR-219-2-3p. Since silencing of miRNA by promoter CpG island methylation may be an important mechanism in tumorgenesis, GC cells were treated with 5-aza-2'-deoxycytidine and trichostatin A, and expression changes of miR-219-2-3p were subsequently examined by quantitative RT-PCR. Finally, the methylation status of CpG island upstream of miR-219-2-3p was analyzed by methylation-specific PCR in GC tissues (n = 22).
resultsmiR-219-2-3p was down-regulated in GC and cell lines. In addition, the experiments documented the lower expression of miR-219-2-3p in GC specimens with higher grade and later stage tumors. Meanwhile, miR-219-2-3p exerted antiproliferative, proapoptotic, and antimetastatic roles and reduced levels of p-ERK1/2 in GC cells. Furthermore, 5-aza-2'-deoxycytidine and trichostatin A increased the expression (~2 fold) of miR-219-2-3p in GC cells. By methylation-specific PCR, DNA methylation in the upstream region of miR-219-2-3p was detected in both adjacent normal tissues and cancer tissues. As expected, the methylation level was considerably higher in the miR-219-2-3p down-regulated group than up-regulated group.
conclusionsmiR-219-2-3p is potentially involved in gastric cancer progression and metastasis by regulating ERK1/2-related signal pathways, which may provide a novel therapeutic strategy for treatment of gastric cancer. Methylation mechanism may be involved in modulating the expression level of miR-219-2-3p in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.